ATUL2020-07-012020-09-30in-bse-fin:OneOperatingExpenses01Member ATUL2020-07-012020-09-30in-bse-fin:OneOperatingExpenses02Member ATUL2020-07-012020-09-30in-bse-fin:FourOperatingExpenses01Member ATUL2020-07-012020-09-30in-bse-fin:FourOperatingExpenses02Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentRevenue01Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentRevenue02Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentRevenue03Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentRevenue04Member ATUL2020-07-012020-09-30in-bse-fin:FourReportableSegmentRevenue01Member ATUL2020-07-012020-09-30in-bse-fin:FourReportableSegmentRevenue02Member ATUL2020-07-012020-09-30in-bse-fin:FourReportableSegmentRevenue03Member ATUL2020-07-012020-09-30in-bse-fin:FourReportableSegmentRevenue04Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentResults01Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentResults02Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentResults03Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentResults04Member ATUL2020-07-012020-09-30in-bse-fin:FourReportableSegmentResults01Member ATUL2020-07-012020-09-30in-bse-fin:FourReportableSegmentResults02Member ATUL2020-07-012020-09-30in-bse-fin:FourReportableSegmentResults03Member ATUL2020-07-012020-09-30in-bse-fin:FourReportableSegmentResults04Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentAssets01Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentAssets02Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentAssets03Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentAssets04Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentLiabilities01Member ATUL2020-09-30in-bse-fin:OneReportableSegmentLiabilities01Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentLiabilities02Member ATUL2020-09-30in-bse-fin:OneReportableSegmentLiabilities02Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentLiabilities03Member ATUL2020-09-30in-bse-fin:OneReportableSegmentLiabilities03Member ATUL2020-07-012020-09-30in-bse-fin:OneReportableSegmentLiabilities04Member ATUL2020-09-30in-bse-fin:OneReportableSegmentLiabilities04Member ATUL2020-07-012020-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ATUL2020-07-012020-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ATUL2020-07-012020-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ATUL2020-07-012020-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ATUL2020-07-012020-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ATUL2020-07-012020-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ATUL 2020-04-01 2021-03-31 2020-09-30 INR Crores Half yearly Multi segment 2020-07-01 2020-09-30 Unaudited Standalone 9570300000.00 82200000.00 9652500000.00 4018500000.00 437200000.00 -43200000.00 614700000.00 6900000.00 296600000.00 2072400000.00 7403100000.00 2249400000.00 0.00 2249400000.00 565400000.00 -12800000.00 552600000.00 0.00 1696800000.00 0.00 0.00 0.00 0.00 1696800000.00 943000000.00 2639800000.00 0.00 0.00 296600000.00 10 57.21 57.21 0.00 0.00 57.21 57.21 Standalone unaudited financial results for the quarter / six months ended on September 30, 2020tttttttttt ntNotes:ttttttttt ntttttttttt nt1.tThese results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.tttttttt ntttttttttt nt2.tThese results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on October 22, 2020, and approved by the Board of Directors in its meeting held on October 23, 2020 through video conferencing. The Statutory Auditors of the Company have carried out a limited review of the standalone unaudited financial results for the quarter / six months ended on September 30, 2020. Their limited review report does not have any qualification / modification.tttttttt ntttttttttt nt3.tThe Company publishes standalone unaudited financial results along with the consolidated unaudited financial results. In accordance with the Ind AS 108, 'Operating Segments', the Company has disclosed the segment information in the consolidated unaudited financial results and therefore no separate disclosure on segment information is given in the standalone unaudited financial results for the quarter / six months ended on September 30, 2020.tttttttt ntttttttttt nt4.tOther income includes:tttttttt ntta)tExchange rate difference - gain / (loss):ttttttt nttttttttt(` cr)t nttParticularsttQuarter ended ontttSix months ended onttYear ended ont nttttSeptember 30, 2020t June 30, n2020 tSeptember 30, 2019tSeptember 30, 2020tSeptember 30, 2019t March 31, n2020 t nttttUnauditedtUnauditedtUnauditedtUnauditedtUnauditedtAuditedt nttExchange rate difference - gain / (loss)tt (5.68)t (0.89)t 4.36 t (6.57)t 4.35 t 18.59 t ntttttttttt nttb)tSpecial dividend for the year 2019-20 received of ` 30.69 cr (Previous year: ` nil) from an investee company during the six months ended on September 30, 2020.ttttttt ntttttttttt nt5.t Manufacturing facilities of the Company which were shut down in the last week of March 2020 due to countrywide lockdown, resumed operations in a phased manner from the last week of April 2020 after obtaining the requisite approvals. nThe Company has considered possible effects that may result from COVID-19 in preparation of these standalone financial results including recoverability of inventories, trade receivables and other assets. In developing the assumptions relating to future uncertainties in the economic conditions due to COVID-19, it has, at the date of approval of these standalone financial results, used relevant internal and external sources of information including economic forecasts and expects that the carrying amounts of these assets are recoverable. The impact of COVID-19 may be different from that estimated as at the date of approval of these standalone financial results. tttttttt ntttttttttt nt6.tThe Parliament of India has approved the Code on Social Security, 2020 (the Code) which may impact the contributions by the Company towards provident fund, gratuity and ESIC. The Code has been published in the Gazette of India. However, the effective date has not yet been notified. The Company will assess the impact of the Code when it comes into effect and will record related impact, if any, in the period the Code becomes effective. Multi segment 2020-04-01 2020-09-30 Unaudited Standalone 15597800000.00 492900000.00 16090700000.00 6333300000.00 720800000.00 -102700000.00 1223400000.00 9600000.00 591500000.00 3533000000.00 12308900000.00 3781800000.00 0.00 3781800000.00 942600000.00 -27200000.00 915400000.00 0.00 2866400000.00 0.00 0.00 0.00 0.00 2866400000.00 985200000.00 3851600000.00 0.00 0.00 296600000.00 10 96.64 96.64 0.00 0.00 96.64 96.64 Other Expenses 1250300000.00 Power, fuel and water 822100000.00 Other Expenses 2193600000.00 Power, fuel and water 1339400000.00 Life Science Chemicals 3475400000.00 Others 107800000.00 Performance and Other Chemicals 6896000000.00 Share of net profit of joint venture company 0.00 Life Science Chemicals 6184000000.00 Others 194900000.00 Performance and Other Chemicals 11100900000.00 Share of net profit of joint venture company 0.00 10479200000.00 17479800000.00 453300000.00 853300000.00 10025900000.00 16626500000.00 Life Science Chemicals 671200000.00 Others 48200000.00 Performance and Other Chemicals 1593600000.00 Share of net profit of joint venture company 24400000.00 Life Science Chemicals 1181600000.00 Others 43000000.00 Performance and Other Chemicals 2449100000.00 Share of net profit of joint venture company 27200000.00 2337400000.00 3700900000.00 21600000.00 48300000.00 -31100000.00 -332200000.00 2346900000.00 3984800000.00 Life Science Chemicals 8645100000.00 Others 1295900000.00 Performance and Other Chemicals 17012200000.00 Share of net profit of joint venture company 0.00 26953200000.00 18715500000.00 45668700000.00 Life Science Chemicals 3265600000.00 Others 455800000.00 Performance and Other Chemicals 4266100000.00 Share of net profit of joint venture company 0.00 7987500000.00 1932900000.00 9920400000.00